Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
142 hedge funds and large institutions have $428M invested in Progenics Pharmaceuticals Inc in 2017 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 55 increasing their positions, 41 reducing their positions, and 23 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 41
0% more capital invested
Capital invested by funds: $426M → $428M (+$2.07M)
7% less funds holding
Funds holding: 152 → 142 (-10)
35% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 23
35% less call options, than puts
Call options by funds: $1.81M | Put options by funds: $2.78M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$8.89M |
| 2 |
BlackRock
New York
|
+$1.3M |
| 3 |
HP
Hikari Power
Tokyo,
Japan
|
+$1.27M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
+$1.21M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$6.79M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$6.16M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.54M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.34M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.49M |
PGNX Hedge Fund Activity: Q3 2017 in Review
142 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2017, worth a combined $428M — up 0.49% from $426M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of PGNX and 15 opened new positions — a net loss of 8 holders — while 41 trimmed existing stakes and 55 added.
The largest buyer was Ardsley Advisory Partners, adding an estimated $8.89M. The largest seller was Broadfin Capital, exiting entirely with an estimated $6.79M sold.
- 142 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2017, down from 152 in Q2 2017.
- Funds reported $428M of Progenics Pharmaceuticals Inc stock for Q3 2017, up 0.49% quarter-over-quarter.
- 15 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2017 and 23 closed out, a net change of -8 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q3 2017 was Ardsley Advisory Partners, an estimated $8.89M added.
- The largest Progenics Pharmaceuticals Inc seller in Q3 2017 was Broadfin Capital, an estimated $6.79M sold.
Based on aggregated 13F filings for Q3 2017.